ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.400,01
-0,48%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Nuvalent Inc (NUVL)

  7. Nuvalent Inc (NUVL) News

NUVL

Nuvalent (NUVL)

Nuvalent Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NUVL
DatumZeitQuelleÜberschriftSymbolFirma
29/05/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
29/05/202412h30PR Newswire (US)Nuvalent to Participate in the 2024 Jefferies Global Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
17/05/202422h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
16/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
16/05/202422h01PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655NASDAQ:NUVLNuvalent Inc
15/05/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/05/202412h46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NUVLNuvalent Inc
09/05/202412h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
09/05/202412h30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsNASDAQ:NUVLNuvalent Inc
08/05/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
08/04/202422h30PR Newswire (US)Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
05/03/202422h52PR Newswire (US)Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024NASDAQ:NUVLNuvalent Inc
27/02/202413h00Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NUVLNuvalent Inc
27/02/202412h42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NUVLNuvalent Inc
27/02/202412h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
27/02/202412h30PR Newswire (US)Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NUVLNuvalent Inc
27/02/202412h15PR Newswire (US)Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520NASDAQ:NUVLNuvalent Inc
12/02/202412h30PR Newswire (US)Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid TumorsNASDAQ:NUVLNuvalent Inc
01/02/202412h30PR Newswire (US)Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:NUVLNuvalent Inc
09/01/202422h55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/01/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/01/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/01/202422h49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/01/202422h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
09/01/202422h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NUVLNuvalent Inc
08/01/202412h30PR Newswire (US)Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated MilestonesNASDAQ:NUVLNuvalent Inc
28/12/202323h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
26/12/202322h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NUVLNuvalent Inc
21/12/202312h30PR Newswire (US)Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:NUVLNuvalent Inc
20/12/202322h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NUVLNuvalent Inc
 Showing the most relevant articles for your search:NASDAQ:NUVL

Kürzlich von Ihnen besucht

TG
TUI1
Tui
CCOM
SILVER
SILVER
NASDAQ
AAPL
Apple
TG
RHM
Rheinmetall
NYSE
NKE
Nike
TG
D7G
Nel ASA
AMEX
SPY
SPDR S&P 500
NYSE
DIS
Walt Disney
TG
DBK
Deutsche Bank
TG
432
Arbor Metals
NYSE
MCD
McDonalds
TG
ALV
Allianz
TG
MBG
MercedesBenz
USOTC
ADDYY
Adidas (QX)
TG
CBK
Commerzbank
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten